Imaging of pleural masses: Which to choose?—Republished article  by Bruns, Aaron S. & Mastronarde, John G.
ARTICLE IN PRESS
Respiratory Medicine CME (2008) 1, 10–14respiratory MEDICINE
CME$This article was fi
Medicine - CME read
1755-0017/$ - see fr
doi:10.1016/j.rmedc
Corresponding au
E-mail addressesCME ARTICLE
Imaging of pleural masses:
Which to choose?—Republished article$
Aaron S. Bruns, John G. MastronardeDivision of Pulmonary and Critical Care, The Ohio State University Medical Center, 473 West 12th Avenue, Columbus,
OH 43210, USAKEYWORDS
Non-small cell lung
carcinoma;
Pleural neoplasms;
Magnetic resonance
imagingrst published in Re
ers. Readers are r
ont matter & 2008
.2008.02.002
thor. Tel.: +1 614
: Aaron.Bruns@osuSummary
The differential diagnosis of pleural masses is limited. Asbestos-related disease and
invasive bronchogenic carcinoma make up the majority of cases. The diagnostic yield of
biopsies is low, and invasive procedures are often required to achieve diagnosis. A variety
of imaging techniques are available to help differentiate between benign and malignant
disease to help discern which patients to biopsy. While computed tomography has a
relatively good sensitivity and specificity, magnetic resonance imaging (MRI) and positron
emission tomography (PET) both appear to have higher accuracy. MRI has the added benefit
of being an excellent aid in determining surgical resectability of tumors. MRI and PET are
limited, however, by their cost and availability in certain regions.
& 2008 Elsevier Ltd. All rights reserved.Educational aims To briefly review the differential diagnosis of pleural masses.
 To familiarize the reader with the various imaging
modalities available for evaluating pleural-based masses.
 To understand the strengths and weaknesses of each
imaging modality.
Case presentation
A 68-year old woman with a history of diabetes mellitus and
hypertension presented to our outpatient pulmonary clinic forspiratory Medicine, Vol. 102, Issu
equested to cite the original sour
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mc.edu (A.S. Bruns), John.Mastroevaluation of an abnormal chest CT. She initially presented to
her family practitioner with complaints of snoring, poor quality
sleep and excessive daytime sleepiness. A polysomnogram
(PSG) done at that time was negative for obstructive sleep
apnea (OSA), but significant oxygen desaturation was noted
during sleep, and the patient was placed on nocturnal oxygen.
As part of the work-up to discern the etiology of her nocturnal
desaturations, a chest X-ray revealed a possible right lower
lobe lung mass. A chest CTwas then performed (Figure 1) and
is shown below. Positron emission tomography (PET) was then
performed which showed the mass to be hypermetabolic with
a standardized uptake value (SUV) of 7.7.e 3, pp. 328–331 and is re-published for the benefit of Respiratory
ce when citing this article.
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Figure 3 Frozen section of Schwannoma, low magnification, S-
100 stain.
Figure 1 Chest CT.
Figure 2 Spindle cell tumor, low magnification, S-100 stain.
Imaging of pleural masses: Which to choose?—Republished article 11Based on the CT findings, the patient was referred to
radiology for a CT-guided biopsy of the mass. Pathology
(Figure 2) revealed bland-appearing spindle cell prolifera-
tion with collagenous stroma. Immunohistochemical stains
were negative for Ki-67 and calretinin. Stains for S-100 were
strongly positive, suggesting a neural-based tumor.
Based on the pathology findings and the patient’s
symptoms, she was referred to thoracic surgery for
consideration of resection of the mass. During the surgery,
the mass was found to originate from the intercostal nerve
between the fifth and sixth ribs in the posterior mediasti-
num. Frozen sections revealed a schwannoma (Figure 3).
Pleural plaques are found in 20–60% of workers exposed to
asbestos, and are the most common cause of pleural
masses.1,2 Localized pleural tumors include lipomas, lipo-$This article was first published in Respiratory Medicine, Vol. 102, Issu
Medicine - CME readers. Readers are requested to cite the original soursarcomas and fibrous tumors of the pleura. These tumors are
rare, often asymptomatic, and usually have a good prognosis
with resection.2 Bronchogenic carcinoma may invade the
pleura; giving an appearance consistent with a pleural mass.
While malignant mesothelioma and metastatic tumors from
other sites usually present as extensive pleural disease or
effusion, they may occasionally present as discrete pleural
masses as well. As in our case, masses in the posterior
mediastinum can masquerade as pleural masses depending
on the imaging modality chosen. Therefore, it is important
to choose the proper imaging modality to fully evaluate
pleural masses.
Chest radiography
Radiography is commonly used as an initial screening test
when evaluating patients with suspected lung disease or
pleural abnormalities. However, conventional radiography is
extremely limited in its ability to differentiate between
benign and malignant pleural processes, as well as pleural
processes from parenchymal ones.3 When evaluating for
asbestos-related disease, radiography has a sensitivity of
only 13–53%.4 In addition, differentiating malignant from
benign disease is often difficult using less invasive diagnostic
techniques, such as pleurocentesis or percutaneous pleural
biopsy5; VATS or open thoracotomy is often required. Thus, if
proper imaging can narrow the diagnosis, more invasive
procedures can be avoided in some cases.
Computed tomography
When compared to radiography, the use of computed
tomography is superior in differentiating between pleural
and parenchymal disease, determining the location and
extent of disease, and can occasionally allow characteriza-
tion of tissue based on signal attenuation.6 In addition, CT is
more sensitive in detecting pleural plaques7 and in detectinge 3, pp. 328–331 and is re-published for the benefit of Respiratory
ce when citing this article.
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Table 1 Sensitivities and specificities for malignant
disease using CT scan.
Sensitivity
(%)
Specificity
(%)
Pleural rind 41 100
Nodular thickening 51 94
Parietal thickening 41 cm 36 94
Mediastinal pleural disease 56 88
A.S. Bruns, J.G. Mastronarde12chest wall/pleural invasion by a peripheral tumor8 (although
CT is also limited in this ability, see discussion of CT versus
MRI below).
One of the earliest studies investigating the use of CT in
evaluating pleural disease was performed by Leung et al.9
This was a retrospective study evaluating the CT findings in
71 patients with pleural disease who all had definitive
pathologic diagnoses. Several findings were more signifi-
cantly associated with malignant disease than with benign
disease. The results of this study are summarized in Table 1.
In addition, it was noted that pleural calcification was
suggestive of a benign process, seen in 16 of 35 patients with
benign disease, versus three of 39 with malignant disease.
In a more recent investigation of 42 patients with pleural
disease evaluated by CT scanning, mediastinal pleural
involvement and pleural nodularity were again found to be
more common in malignant disease.10 Pleural contour
irregularity and infiltration of the chest wall or diaphragm
were other features more often associated with malignant
disease. 25 of the 27 cases of malignancy had at one or more
of these features, versus only two of 15 cases of benign
disease for a sensitivity of 93% and a specificity of 87% for
detecting malignant disease.
Magnetic resonance imaging (MRI)
A major advantage of using MRI is its superior soft tissue
contrast-resolution and spatial resolution.11 As a result, MRI
is particularly good at demonstrating infiltration of the chest
wall or other adjacent tissues by malignant disease, which
becomes important when determining resectability.11,12 In a
study of 34 patients with pleural lesions evaluated by MRI,
high signal intensity on T2-weighted images was associated
with a specificity of 87%, sensitivity of 100%, and negative
predictive value of 100% in detecting malignant lesions.13
CT versus MRI
Most of the data in the use of MRI concerns its comparison to
CT scanning in the evaluation of pleural masses. Initially,
when CT and MRI were in their youth, a major advantage of
MRI in evaluation of the chest was its ability to image the
body in multiple planes. However, with modern computer
technology and 3D reconstruction, CT is now able to provide
the same information, making MRI less superior in this area.$This article was first published in Respiratory Medicine, Vol. 102, Issu
Medicine - CME readers. Readers are requested to cite the original sourIn the previous study by Falaschi et al.13 all the patients
enrolled also received a CT scan during the evaluation.
Based on morphologic features alone, six of the 34 lesions
were incorrectly identified using CT. Using these six, MRI was
able to correctly identify all of them using long-TR weighted
images.
The article by Hierholzer et al.10 previously mentioned
also compared CT and MRI in the evaluation of pleural
diseases. Using morphologic criteria, the features of
malignant disease were similar to that of CT: mediastinal
pleural involvement, nodularity, contour irregularity and
infiltration of the chest wall or diaphragm. MRI was able to
discern an additional four cases of chest wall or diaphragm
infiltration over CT, which is important when staging and
determining resectability. When evaluating pleural disease
using signal intensity, 20 of 22 malignant cases demon-
strated signal hyperintensity versus only three of 15 benign
cases. The combination of morphologic criteria and signal
intensity was able to correctly identify all 27 cases of
malignant disease. The overall result revealed MRI as
superior in determining chest wall and diaphragm invasion
with CT being superior in detecting calcification (a marker of
benignity) and bony destruction. CT also has the advantage
of being superior in guidance for biopsy.14
Other studies comparing CT versus MRI have confirmed
the above results and have also shown that MRI is better at
discerning encasement/infiltration of vessels, which is more
important for parenchymal than pleural disease, but gives
further strength to its use in pre-operative evaluation.15
Ultrasound
The use of ultrasound in the evaluation of pleural masses is
limited. While useful due to its relatively low cost, it is
primarily indicated for use as a guidance tool during
drainage of pleural fluid. CT is markedly superior in its
ability to detect pleural thickening and focal masses
compared to ultrasound.9 Currently, ultrasound is not
recommended in the workup of pleural masses.
Positron emission tomography (PET)
PET is a relatively new imaging technique that has been
particularly useful in the evaluation of solitary pulmonary
nodules for malignant potential as well as for staging of
other malignancies.16,17 A few studies have investigated its
role in the evaluation of pleural masses. In one series of 25
patients, 16 with malignant disease and nine with benign,
PET imaging correctly detected all cases of malignancy, and
seven of the nine cases of benignity.18 An additional study
showed PET imaging as having an accuracy of 92% in
differentiating benign versus malignant disease.19 However,
a large number of the patients in this study had malignant
disease, which may have affected the results.
One of the larger studies evaluating PET imaging involved
92 patients, all of whom had non-small cell lung cancer.20
PET had a sensitivity of 100%, specificity of 71%, PPV of 63%
and NPV of 100% in diagnosing pleural malignancy.e 3, pp. 328–331 and is re-published for the benefit of Respiratory
ce when citing this article.
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Table 2 Summary of various imaging modalities.
Advantages Disadvantages
Plain
radiography
Cost;
availability
Cannot discern
malignant versus
benign disease
Computed
tomography
7Cost;
guidance for
biopsy;
calcification;
detection of
plaques
Limited use
during surgical
evaluation;
lower
sensitivity/
specificity
Ultrasonography Cost; useful for
drainage of
effusion
Difficult to
visualize
plaques or
thickening;
Cannot discern
malignant versus
benign disease
Magnetic
resonance
imaging
Excellent for
discerning
tumor
respectability;
high specificity/
sensitivity
Cost; limited
availability in
some areas
Positron
emission
tomography
High specificity/
sensitivity
Cost;
availability;
limited in use
for resectability
Imaging of pleural masses: Which to choose?—Republished article 13When combined with CT, specificity rose to 76% and PPV
to 67%.
While PET may be useful as a screening tool to decide
when to send a patient for biopsy, it is limited in its ability to
delineate chest wall or diaphragmatic invasion, or to help
determine resectability.
Conclusion
A variety of imaging modalities are currently available for
use in the evaluation of pleural masses. Radiography
is usually a first step, but it is clear that further imag-
ing beyond this is required. However, further research
is required in order to determine which imaging modality
(or combination of modalities) is the most useful next step
prior to obtaining biopsies. Table 2 provides a summary
of the advantages and disadvantages of the modalities
discussed.
CME section
This article has been accredited for CME learning by the
European Board of Accreditation in Pneumology (EBAP). You
can receive 1 CME credit by successfully answering these
questions online.$This article was first published in Respiratory Medicine, Vol. 102, Issu
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(B) Complete the answers online, and receive your final
score upon completion of the test
(C) Should you successfully complete the test, you may
download your accreditation certificate (subject to an
administrative charge)
1. When evaluating a pleural mass which of the following
statements is true?
(a) Plain radiography usually identifies definitive signs of
malignancy
(b) Plain radiography can differentiate parenchymal and
pleural massess with high specificity
(c) Tomography has no advantages over plain
radiography
(d) Surgical biopsy can be avoided or size of biopsy
limited by CT assessment
(e) If evaluating asbestos exposure biopsy will always be
required
2. When assessing the likelihood of a malignant versus
benign etiology for a lung mass which of the following
statements is true?
(a) Pleural calcifications increase the likelihood of
malignant processes
(b) Pleural nodularity is a common finding in benign
processes
(c) The mediastinum should be evaluated for pleural
involvement
(d) Only very large tumors will show irregular contours
(e) Imaging studies perform very poorly in identifying
benign conditions
3. The advantages of MRI assessment compared to CT
include all of the following except?
(a) The MRI has lower radiation exposure
(b) The MRI has better spatial resolution
(c) The MRI has better 3D capabilities
(d) The MRI is better at determining resectability of the
lesion
(e) Signal hyperintensity is important in identifying
benign disease
4. When considering additional imaging for pleural lesions
which of the following statements is true?
(a) Ultrasound helps identify pleural thickening
(b) Ultrasound is a good adjunct to CT
(c) PET assessment is not better than CT in determining
malignant status of lesions
(d) The negative predictive ability of PET (ability to say
not malignant) is close to 100%
(e) PER is as good or better than MRI in determining
resectability
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